Last updated on August 2019

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Detailed Study Description

The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or total colorectal events.

Clinical Study Identifier: NCT01349881

Find a site near you

Start Over

El Camino Hospital

Mountain View, CA United States
0.23miles
  Connect »

Palo Alto Medical Foundation-Camino Division

Mountain View, CA United States
0.23miles
  Connect »

Palo Alto Medical Foundation-Gynecologic Oncology

Mountain View, CA United States
0.23miles
  Connect »

Palo Alto Medical Foundation-Sunnyvale

Sunnyvale, CA United States
3.36miles
  Connect »

Palo Alto Medical Foundation Health Care

Palo Alto, CA United States
5.41miles
  Connect »

Kaiser Permanente Medical Center - Santa Clara

Santa Clara, CA United States
6.05miles
  Connect »

Kaiser Permanente-Redwood City

Redwood City, CA United States
9.52miles
  Connect »